Transforming the Treatment of Neuromuscular Diseases

Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases.

Creating the new generation of genetic therapies

Advancing revolutionary therapies to treat degenerative neuromuscular diseases

Careers at PepGen

Seeking passionate individuals who can help us to create therapies to improve the future of people living with neuromuscular diseases

Latest Updates

PepGen Appoints Laurie Keating as Chair of Board of Directors

Keating brings strong experience as a life science executive and Board member BOSTON, January 19, …

Read More →

PepGen Appoints Vice President of Program Management and Promotes Sonia Bracegirdle, Ph.D., to Senior Vice President, Strategy & Operations

PepGen Appoints Vice President of Program Management and Promotes Sonia Bracegirdle, Ph.D., to Senior Vice …

Read More →

PepGen Bolsters R&D Team with Appointment of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development

BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) — PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular …

Read More →